• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Onco360 Chosen as Pharmacy Provider for Rezurock


The FDA had approved Kadmon's therapy for graft-versus-host disease July 16.

Kadmon Pharmaceuticals has selected Onco360 as the pharmacy provider for Rezurock (belumosudil). Onco360 in Louisville, K.Y., is a provider of oncology pharmacy services and dispenses nationally through its network of URAC-, ACHC-, and NABP digital-accredited pharmacies. It is a specialty pharmacy brand of PharMerica Corporation.

The FDA approved Rezurock on July 16 for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy.

Rezurock is expected to be available by late August 2021

“As a provider of this key treatment, Onco360 is committed to supporting the highly specialized needs of chronic GVHD patients,” Benito Fernandez, chief commercial officer, Onco360, said in a statement.

Rezurock is the first FDA-approved small molecule inhibitor of ROCK2, a signaling pathway that modulates inflammatory responses and fibrotic processes. The approval is based on safety and efficacy results from ROCKstar (KD025-213), a randomized, open-label, multicenter pivotal trial of Rezurock in 65 patients with cGVHD who had received two to five prior lines of systemic therapy.

The therapy achieved an overall response rate of 75% through cycle 7 day 1 of treatment with 6% of patients achieving a complete response and 69% achieving a partial response. Sixty-two percent (62%) of responders did not require new systemic therapy for at least 12 months following response.

Related Videos
Expert on Hematology/Oncology
Related Content
© 2024 MJH Life Sciences

All rights reserved.